Research Progress of the Therapeutic Antibodies in the Treatment of Brain Diseases

Chu-lin ZHANG,Yu LIU

DOI: https://doi.org/10.19526/j.cnki.1005-8915.20170415

2017-01-01

Abstract:Central nervous system diseases are becoming more and more harmful to human health,because the tight junction of the cerebral capillaries cells on blood-brain barrier,greatly limit the drugs delivery into the brain tissue to play a role.The traditional brain therapeutic antibodies have been developed in the recent years' clinical results which are not ideal in the phase Ⅲ clinical and the main reason for this results is that they can't pass or fail to reach a therapeutic dose in the brain,so how to make the antibody pass the BBB in a stable therapeutic dose in the early stages of the disease has becomes the key to the study on treatment of central nervous system diseases.In many of the strategies to make drugs into the brain,using the blood-brain barrier's own transport system,and the receptor-mediated endocytosis systems are responsible for the transport across the BBB of specific endogenous large molecules which has the wide development prospects.Clinical studies have shown that targeting transferrin receptor (TfR),insulin receptor (IR) and other targets'antibodies can effectively promote the drug across the brain to play a role.The tendency of the antibody to treat the central nervous system disease is generated by fusion of targeted antibody with therapeutic antibody to design the bispecific antibody format,so that it can pass the blood-brain barrier through the specific target and reach the therapeutic dose in the brain to play a role.This article will discuss the application and the research tendency of the antibody in central nervous system diseases in detail.